Mirna Therapeutics Inc. (MIRN) Trading 6% Higher
Shares of Mirna Therapeutics Inc. (NASDAQ:MIRN) shot up 6% during mid-day trading on Friday . The company traded as high as $3.41 and last traded at $3.20, with a volume of 113,389 shares trading hands. The stock had previously closed at $3.02.
A number of research firms recently issued reports on MIRN. Leerink Swann lowered Mirna Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $10.00 to $4.00 in a research note on Monday, August 15th. Oppenheimer Holdings Inc. boosted their price objective on Mirna Therapeutics from $7.00 to $13.00 and gave the company an “outperform” rating in a research note on Tuesday, August 16th. Zacks Investment Research lowered Mirna Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Citigroup Inc. lowered Mirna Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $7.00 to $4.50 in a research note on Tuesday, August 16th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $14.00 target price on shares of Mirna Therapeutics in a research note on Friday, May 13th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Mirna Therapeutics has a consensus rating of “Hold” and a consensus target price of $8.10.
The firm has a 50-day moving average price of $4.18 and a 200 day moving average price of $4.36. The firm’s market cap is $70.42 million.
Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.